News Biomm S.A.

Equities

BIOM3

BRBIOMACNOR2

Delayed Sao Paulo Other stock markets 09:27:30 2024-04-30 am EDT			5-day change	1st Jan Change
17.38 ^BRL	+6.23%		+8.62%	+200.69%

Apr. 18	Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil	MT
Apr. 17	Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil	Apr. 17	MT
Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A	Apr. 17	CI
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Biomm S A : Webcast Presentation 3Q23	Nov. 14	PU
Biomm S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Biomm S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Biomm S A : Apresentação de resultados 2T23	23-08-09	PU
Bio-Thera Solutions Expands Partnership with Biomm in Brazil with Addition of BAT2206, A Stelara Biosimilar	23-06-16	CI
Biomm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-23	CI
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-23	CI
Biomm S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Biomm S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
Biomm S A : Presentation of 1Q22 Results	22-05-15	PU
Biomm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-25	CI
Biomm S A : Comunicado ao Mercado	22-03-03	PU
Lupin Enters Partnership to Market Biosimilar Pegfilgrastim in Brazil	21-12-05	MT
CytoDyn : Receives Clearance from Brazil's FDA (ANVISA) to Commence a Pivotal Phase 3 Trial in Critically Ill COVID-19 Patients with IV Administration of Four Doses (700mg/week)	21-09-23	AQ
Biomm S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Biomm S.A.

Equities

BIOM3

BRBIOMACNOR2

Summary

Filters